Also, diosgenin may primarily act over two cytoplasmic targets FGFR2 and SRC to prevent the interaction with NF-kB (prevents cell self-renewal) and metastatic spread respectively (Figure 14) and may also modulate other pathways within the breast cancer pathogenesis (Figure 15) which was evidenced during KEGG pathway analysis. This evidence concerns the gene NFKB1 and breast carcinoma.